In vitro and molecular docking studies on a novel Brevibacillus borstelensis NOB3 bioactive compounds as anticancer, anti-inflammatory, and antimicrobial activity

Abstract

Cancerous tumor growth and inflammation stimulate the search for novel anticancer drugs. This pioneering study isolated Brevibacillus borstelensis NOB3 from a solar saltern and tested its bioactive substances for anticancer, antimicrobial, and anti-inflammatory activity. An in-silico test against HeLa cells was followed by an in-vitro MTT test. Agar well diffusion was used to examine the activity of the bioactive compounds of B. borstelensis NOB3 against spectrum human pathogenic bacteria and fungi. The highest clear zone was found with Bacillus subtilis (30 mm), followed by Escherichia coli and Candida albicans (28 mm); Pseudomonas aeruginosa and Staphylococcus aureus had a smaller zone of inhibition (25 mm). The minimum inhibitory concentration (MIC), was 31.25 g/ml against E. coli, followed by 62.5 g/ml against B. subtilis, P. aeruginosa, and C. albicans. Twenty-two bioactive substances were identified by (GC-MS). The binding energy of pyrazine, n-hexadecenoic acid, and oleic acid was measured for the cervical cancer target protein, and the findings were ‒5.1 kcal/mol, ‒4.6 kcal/mol, and ‒4.7 kcal/mol, respectively. In-vitro tests revealed potential action against the HeLa cell line with a half-maximal inhibitory concentration (IC50) of 68.46 g/ml. The novel halophilic B. borstelensis NOB3 has the potential to produce bioactive compounds for drug development.